
- BridgeBio Pharma (BBIO) has surged 145% over the past year, reaching an all-time high of $75.10.
- BBIO maintains a strong technical profile with a 100% “Buy” Barchart opinion.
- Revenue is projected to grow 123% this year and 79.63% next year, though earnings will dip 61.11% before rebounding 44.41%.
- Despite bullish analyst sentiment, BBIO’s 12.3% short interest and volatility warrant caution.